Targeting the Oncoprotein MDMX as a Novel Treatment for Triple Negative Breast Cancer

靶向癌蛋白 MDMX 作为三阴性乳腺癌的新型治疗方法

• 批准号: nhmrc : 1123057
• 负责人: A/Pr Elgene Lim
• 金额: $ 38.34万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-oncoprotein-mdmx-breast-cancer/947089
• 关键词: Targeting; Oncoprotein; MDMX; Novel; Treatment

Breast cancer (BrCa) is a leading cause of cancer death in women worldwide. BrCas unable to respond to current therapies have the worst outcomes. We propose a novel strategy to treat these cancers, based on our new findings. Our two protein targets are: (1) MDMX, that we found drives BrCa with its partner, (2) mutant p53, which causes cancer spread. We plan to directly target these drivers of aggressive BrCas, using new drugs that individually show great promise in trials in a number of cance

乳腺癌(BRCA)是全球女性癌症死亡的主要原因。无法对目前的治疗方法做出反应的Brca患者的结果最差。基于我们的新发现，我们提出了一种治疗这些癌症的新策略。我们的两个蛋白质靶点是：(1)MDMX，我们发现它与其伴侣一起驱动BRCA，(2)突变的p53，它会导致癌症扩散。我们计划直接针对这些攻击性BrCA的驱动因素，使用在一些癌症的试验中个别显示出巨大前景的新药